AHA Scientific Sessions 2026 Abstract
Evolocumab linked to fewer deaths in high-risk adults
Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.Over three years, deaths occurred in 1.4% of evolocumab users versus 2.7% of alirocumab users across 2,610 matched pairs.

Cohort studyEvolocumab
Who was studiedAdults with atherosclerotic disease or high-risk diabetes, against alirocumab users
What changedDeath from any cause was lower among evolocumab users: 1.4% versus 2.7% among alirocumab users
The catchHealth or prescribing differences missed by matching could contribute to the mortality association



